European Life Sciences CEO Forum 2019
25 & 26 February 2019 / Zurich / Switzerland
Madiha Derouazi and Laurence de Schoulepnikoff attending
A novel approach to therapeutic vaccines
AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
First-in-class immunisation technology
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
Transforming the prospects of cancer patients
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
Strategic partnerships and collaborations
Our strategy is to develop KISIMA® and its current indications in oncology through to phase II, in-house or through strategic partnerships.
Latest
News
- AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round 12 November 2018
- Amal Therapeutics featured in September edition of BioPharma Dealmaker (Springer-Nature) 18 September 2018
- AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round 5 September 2017
Events
BIO International Convention 2019
3 to 6 June 2019 / Philadelphia / USA
Madiha Derouazi and Laurence de Schoulepnikoff attendingAACR Annual Meeting 2019
March 29 – Apr 3, 2019 / Atlanta / USA
Jean-François Mayol attending
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
